- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Clinical Psychopharmacology offers a comprehensive guide to clinical practice that explores two major aspects of the field: the clinical research that exists to guide clinical practice of psychopharmacology, and the application of that knowledge with attention to the individualized aspects of clinical practice. The text consists of 50 chapters, organized into 6 sections, focusing on disease-modifying effects, non-DSM diagnostic concepts, essential facts about the most common drugs, and both the benefits and harms of drugs.
Andere Kunden interessierten sich auch für
- Arash AnsariPsychopharmacology98,99 €
- Seminars in Clinical Psychopharmacology74,99 €
- Joanna MoncrieffA Straight Talking Introduction to Psychiatric Drugs18,99 €
- The Benzodiazepines Crisis96,99 €
- John D. PrestonChild and Adolescent Clinical Psychopharmacology Made Simple32,99 €
- Psychiatry Practice Boosters, Second Edition: Insights from research to enhance your clinical work51,99 €
- Karen SimpsonSpinal Interventions in Pain Management107,99 €
-
-
-
Clinical Psychopharmacology offers a comprehensive guide to clinical practice that explores two major aspects of the field: the clinical research that exists to guide clinical practice of psychopharmacology, and the application of that knowledge with attention to the individualized aspects of clinical practice. The text consists of 50 chapters, organized into 6 sections, focusing on disease-modifying effects, non-DSM diagnostic concepts, essential facts about the most common drugs, and both the benefits and harms of drugs.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Oxford University Press
- Seitenzahl: 600
- Erscheinungstermin: 4. Januar 2019
- Englisch
- Abmessung: 251mm x 173mm x 36mm
- Gewicht: 1220g
- ISBN-13: 9780199995486
- ISBN-10: 0199995486
- Artikelnr.: 54432995
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- 06621 890
- Verlag: Oxford University Press
- Seitenzahl: 600
- Erscheinungstermin: 4. Januar 2019
- Englisch
- Abmessung: 251mm x 173mm x 36mm
- Gewicht: 1220g
- ISBN-13: 9780199995486
- ISBN-10: 0199995486
- Artikelnr.: 54432995
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- 06621 890
S. Nassir Ghaemi, MD, MPH, is a Professor of Psychiatry and Pharmacology at Tufts University School of Medicine, and a Lecturer on Psychiatry at Harvard Medical School in Boston, Massachusetts. He is also Director of Translational Medicine-Neuroscience at Novartis Institutes for Biomedical Research in Cambridge, Massachusetts. Dr. Ghaemi has been active in clinical psychopharmacology practice and research for over two decades, with specialization in depression and bipolar illness. He holds degrees in philosophy and public health, and is a highly published scientific investigator.
* Section I: Basic Psychopharmacology
* Chapter 1: A New Psychopharmacology Nomenclature
* Chapter 2: Fundamentals of Neurobiology
* Chapter 3: Fundamental Psychotropic Drug Structures and Mechanisms
* Section II: Clinical Research Concepts for Psychopharmacology
* Chapter 4: The Limitations of Clinical Experience
* Chapter 5: Evidence-based Medicine: Pro and Con
* Chapter 6: Maintenance Treatment Designs: "Enriched," But Not Better
* Chapter 7: Negative Studies: The Failure to Know What Isn't Known
* Chapter 8: Side Effects and Generalizability: Beyond p-values
* Section III: Clinical Psychopharmacology of Drug Classes
* Chapter 9: Monoamine Agonists ("Antidepressants"), Including Dopamine
Agonists ("Stimulants")
* Chapter 10: Dopamine Blockers ("Antipsychotics")
* Chapter 11: Second Messenger Modifiers ("Mood Stabilizers")
* Chapter 12: Gabaergic Agonists ("Anxiolytics")
* Chapter 13: Other Agents (Glutamate Antagonists, Antihistamines,
Melatonin Agonists, and Others)
* Chapter 14: Drug Class Summaries and Dosing Guidelines
* Chapter 15: Index of Selected Commonly Used Drugs with Brief
Summaries
* Section IV: Clinical Psychopharmacology of Diseases and Syndromes
* Chapter 16: Hippocratic Psychopharmacology: A Non-DSM Approach to
Practice
* Chapter 17: Beyond Symptoms: Diagnostic Validators
* Chapter 18: The Concept of a Diagnostic Hierarchy
* Chapter 19: Treatment of Affective Illnesses
* Chapter 20: Anxiety Conditions
* Chapter 21: Treatment of Personality
* Chapter 22: Schizophrenia and Schizoaffective Conditions
* Chapter 23: Addictions
* Chapter 24: PTSD
* Section V: Special Topics
* Chapter 25: Carcinogenicity of Psychotropic Drugs
* Chapter 26: Seasonal Affective Illness
* Chapter 27: Suicide
* Chapter 28: Children
* Chapter 29: Older Persons
* Chapter 30: Women
* Chapter 31: Ethnic and Racial Groups
* Chapter 32: Psychopharmacology in Medical Illnesses
* Chapter 33: Polypharmacy
* Chapter 34: Cultural Aspects of Psychopharmacology
* Chapter 35: Treatment versus Enhancement
* Chapter 36: The Pharmaceutical Industry
* Chapter 37: Drug Discovery: Future Treatments
* Section VI: The Art of Psychopharmacology
* Chapter 38: The Diagnostic Interview
* Chapter 39: The "Med Check"
* Chapter 40: The Placebo Effect
* Chapter 41: Legal Aspects of Psychopharmacology Practice
* Chapter 42: Psychology of Psychopharmacology
* Chapter 43: Innovation in Clinical Practice
* Chapter 44: Clinical Cases
* Chapter 45: Curbside Consults: Questions and Answers
* Chapter 46: Key Research Studies in Clinical Psychopharmacology
* Chapter 47: Historical Insights in Psychopharmacology
* Chapter 48: Reflections on the Art of Psychopharmacology
* Chapter 49: Ten Fallacies and Ten Truths of Psychopharmacology -
Explained
* Appendices
* Appendix I: Mixed States
* Appendix II: Bipolar or Borderline?
* Appendix III: ADD in Children and Adults
* Appendix IV: Schizoaffective Illness
* Chapter 1: A New Psychopharmacology Nomenclature
* Chapter 2: Fundamentals of Neurobiology
* Chapter 3: Fundamental Psychotropic Drug Structures and Mechanisms
* Section II: Clinical Research Concepts for Psychopharmacology
* Chapter 4: The Limitations of Clinical Experience
* Chapter 5: Evidence-based Medicine: Pro and Con
* Chapter 6: Maintenance Treatment Designs: "Enriched," But Not Better
* Chapter 7: Negative Studies: The Failure to Know What Isn't Known
* Chapter 8: Side Effects and Generalizability: Beyond p-values
* Section III: Clinical Psychopharmacology of Drug Classes
* Chapter 9: Monoamine Agonists ("Antidepressants"), Including Dopamine
Agonists ("Stimulants")
* Chapter 10: Dopamine Blockers ("Antipsychotics")
* Chapter 11: Second Messenger Modifiers ("Mood Stabilizers")
* Chapter 12: Gabaergic Agonists ("Anxiolytics")
* Chapter 13: Other Agents (Glutamate Antagonists, Antihistamines,
Melatonin Agonists, and Others)
* Chapter 14: Drug Class Summaries and Dosing Guidelines
* Chapter 15: Index of Selected Commonly Used Drugs with Brief
Summaries
* Section IV: Clinical Psychopharmacology of Diseases and Syndromes
* Chapter 16: Hippocratic Psychopharmacology: A Non-DSM Approach to
Practice
* Chapter 17: Beyond Symptoms: Diagnostic Validators
* Chapter 18: The Concept of a Diagnostic Hierarchy
* Chapter 19: Treatment of Affective Illnesses
* Chapter 20: Anxiety Conditions
* Chapter 21: Treatment of Personality
* Chapter 22: Schizophrenia and Schizoaffective Conditions
* Chapter 23: Addictions
* Chapter 24: PTSD
* Section V: Special Topics
* Chapter 25: Carcinogenicity of Psychotropic Drugs
* Chapter 26: Seasonal Affective Illness
* Chapter 27: Suicide
* Chapter 28: Children
* Chapter 29: Older Persons
* Chapter 30: Women
* Chapter 31: Ethnic and Racial Groups
* Chapter 32: Psychopharmacology in Medical Illnesses
* Chapter 33: Polypharmacy
* Chapter 34: Cultural Aspects of Psychopharmacology
* Chapter 35: Treatment versus Enhancement
* Chapter 36: The Pharmaceutical Industry
* Chapter 37: Drug Discovery: Future Treatments
* Section VI: The Art of Psychopharmacology
* Chapter 38: The Diagnostic Interview
* Chapter 39: The "Med Check"
* Chapter 40: The Placebo Effect
* Chapter 41: Legal Aspects of Psychopharmacology Practice
* Chapter 42: Psychology of Psychopharmacology
* Chapter 43: Innovation in Clinical Practice
* Chapter 44: Clinical Cases
* Chapter 45: Curbside Consults: Questions and Answers
* Chapter 46: Key Research Studies in Clinical Psychopharmacology
* Chapter 47: Historical Insights in Psychopharmacology
* Chapter 48: Reflections on the Art of Psychopharmacology
* Chapter 49: Ten Fallacies and Ten Truths of Psychopharmacology -
Explained
* Appendices
* Appendix I: Mixed States
* Appendix II: Bipolar or Borderline?
* Appendix III: ADD in Children and Adults
* Appendix IV: Schizoaffective Illness
* Section I: Basic Psychopharmacology
* Chapter 1: A New Psychopharmacology Nomenclature
* Chapter 2: Fundamentals of Neurobiology
* Chapter 3: Fundamental Psychotropic Drug Structures and Mechanisms
* Section II: Clinical Research Concepts for Psychopharmacology
* Chapter 4: The Limitations of Clinical Experience
* Chapter 5: Evidence-based Medicine: Pro and Con
* Chapter 6: Maintenance Treatment Designs: "Enriched," But Not Better
* Chapter 7: Negative Studies: The Failure to Know What Isn't Known
* Chapter 8: Side Effects and Generalizability: Beyond p-values
* Section III: Clinical Psychopharmacology of Drug Classes
* Chapter 9: Monoamine Agonists ("Antidepressants"), Including Dopamine
Agonists ("Stimulants")
* Chapter 10: Dopamine Blockers ("Antipsychotics")
* Chapter 11: Second Messenger Modifiers ("Mood Stabilizers")
* Chapter 12: Gabaergic Agonists ("Anxiolytics")
* Chapter 13: Other Agents (Glutamate Antagonists, Antihistamines,
Melatonin Agonists, and Others)
* Chapter 14: Drug Class Summaries and Dosing Guidelines
* Chapter 15: Index of Selected Commonly Used Drugs with Brief
Summaries
* Section IV: Clinical Psychopharmacology of Diseases and Syndromes
* Chapter 16: Hippocratic Psychopharmacology: A Non-DSM Approach to
Practice
* Chapter 17: Beyond Symptoms: Diagnostic Validators
* Chapter 18: The Concept of a Diagnostic Hierarchy
* Chapter 19: Treatment of Affective Illnesses
* Chapter 20: Anxiety Conditions
* Chapter 21: Treatment of Personality
* Chapter 22: Schizophrenia and Schizoaffective Conditions
* Chapter 23: Addictions
* Chapter 24: PTSD
* Section V: Special Topics
* Chapter 25: Carcinogenicity of Psychotropic Drugs
* Chapter 26: Seasonal Affective Illness
* Chapter 27: Suicide
* Chapter 28: Children
* Chapter 29: Older Persons
* Chapter 30: Women
* Chapter 31: Ethnic and Racial Groups
* Chapter 32: Psychopharmacology in Medical Illnesses
* Chapter 33: Polypharmacy
* Chapter 34: Cultural Aspects of Psychopharmacology
* Chapter 35: Treatment versus Enhancement
* Chapter 36: The Pharmaceutical Industry
* Chapter 37: Drug Discovery: Future Treatments
* Section VI: The Art of Psychopharmacology
* Chapter 38: The Diagnostic Interview
* Chapter 39: The "Med Check"
* Chapter 40: The Placebo Effect
* Chapter 41: Legal Aspects of Psychopharmacology Practice
* Chapter 42: Psychology of Psychopharmacology
* Chapter 43: Innovation in Clinical Practice
* Chapter 44: Clinical Cases
* Chapter 45: Curbside Consults: Questions and Answers
* Chapter 46: Key Research Studies in Clinical Psychopharmacology
* Chapter 47: Historical Insights in Psychopharmacology
* Chapter 48: Reflections on the Art of Psychopharmacology
* Chapter 49: Ten Fallacies and Ten Truths of Psychopharmacology -
Explained
* Appendices
* Appendix I: Mixed States
* Appendix II: Bipolar or Borderline?
* Appendix III: ADD in Children and Adults
* Appendix IV: Schizoaffective Illness
* Chapter 1: A New Psychopharmacology Nomenclature
* Chapter 2: Fundamentals of Neurobiology
* Chapter 3: Fundamental Psychotropic Drug Structures and Mechanisms
* Section II: Clinical Research Concepts for Psychopharmacology
* Chapter 4: The Limitations of Clinical Experience
* Chapter 5: Evidence-based Medicine: Pro and Con
* Chapter 6: Maintenance Treatment Designs: "Enriched," But Not Better
* Chapter 7: Negative Studies: The Failure to Know What Isn't Known
* Chapter 8: Side Effects and Generalizability: Beyond p-values
* Section III: Clinical Psychopharmacology of Drug Classes
* Chapter 9: Monoamine Agonists ("Antidepressants"), Including Dopamine
Agonists ("Stimulants")
* Chapter 10: Dopamine Blockers ("Antipsychotics")
* Chapter 11: Second Messenger Modifiers ("Mood Stabilizers")
* Chapter 12: Gabaergic Agonists ("Anxiolytics")
* Chapter 13: Other Agents (Glutamate Antagonists, Antihistamines,
Melatonin Agonists, and Others)
* Chapter 14: Drug Class Summaries and Dosing Guidelines
* Chapter 15: Index of Selected Commonly Used Drugs with Brief
Summaries
* Section IV: Clinical Psychopharmacology of Diseases and Syndromes
* Chapter 16: Hippocratic Psychopharmacology: A Non-DSM Approach to
Practice
* Chapter 17: Beyond Symptoms: Diagnostic Validators
* Chapter 18: The Concept of a Diagnostic Hierarchy
* Chapter 19: Treatment of Affective Illnesses
* Chapter 20: Anxiety Conditions
* Chapter 21: Treatment of Personality
* Chapter 22: Schizophrenia and Schizoaffective Conditions
* Chapter 23: Addictions
* Chapter 24: PTSD
* Section V: Special Topics
* Chapter 25: Carcinogenicity of Psychotropic Drugs
* Chapter 26: Seasonal Affective Illness
* Chapter 27: Suicide
* Chapter 28: Children
* Chapter 29: Older Persons
* Chapter 30: Women
* Chapter 31: Ethnic and Racial Groups
* Chapter 32: Psychopharmacology in Medical Illnesses
* Chapter 33: Polypharmacy
* Chapter 34: Cultural Aspects of Psychopharmacology
* Chapter 35: Treatment versus Enhancement
* Chapter 36: The Pharmaceutical Industry
* Chapter 37: Drug Discovery: Future Treatments
* Section VI: The Art of Psychopharmacology
* Chapter 38: The Diagnostic Interview
* Chapter 39: The "Med Check"
* Chapter 40: The Placebo Effect
* Chapter 41: Legal Aspects of Psychopharmacology Practice
* Chapter 42: Psychology of Psychopharmacology
* Chapter 43: Innovation in Clinical Practice
* Chapter 44: Clinical Cases
* Chapter 45: Curbside Consults: Questions and Answers
* Chapter 46: Key Research Studies in Clinical Psychopharmacology
* Chapter 47: Historical Insights in Psychopharmacology
* Chapter 48: Reflections on the Art of Psychopharmacology
* Chapter 49: Ten Fallacies and Ten Truths of Psychopharmacology -
Explained
* Appendices
* Appendix I: Mixed States
* Appendix II: Bipolar or Borderline?
* Appendix III: ADD in Children and Adults
* Appendix IV: Schizoaffective Illness